The FDA approved a label update with a new titration schedule for donanemab (Kisunla), an anti-amyloid drug approved to treat ...

A research team from Virginia Commonwealth University has found that a drug currently in clinical trials for brain disorders ...

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

Neurons that die early in Alzheimer’s help drive brain waste removal. Treating this process sooner could change outcomes.

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

The annual review of clinical trials for Alzheimer’s highlights a growing number of active trials and drugs that could help ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope. “Alzheimer’s disease is a specific condition resulting from an abnormal biological ...